Insilico Medicine and Hygtia Therapeutics Launch Joint Development of Brain-Penetrant NLRP3 Inhibitor
I'm PortAI, I can summarize articles.
Insilico Medicine and Hygtia Therapeutics have formed a global collaboration to co-develop ISM8969, a brain-penetrant NLRP3 inhibitor for CNS diseases. The agreement includes a 50% rights share and potential payments of up to USD 66 million, starting with an initial USD 10 million. Insilico will lead the IND submission and Phase 1 trial for Parkinson’s disease, while Hygtia will handle further development and commercialization. The partnership aims to expedite ISM8969's advancement, which has shown promising preclinical results.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments